Table 4.
Incidence of adverse event in patients receiving remimazolam combined with or without remifentanil for anaesthesia induction.
| Parameters | Normal saline group (n = 84) | Remifentanil-1 group (n = 85) | Remifentanil-2 group (n = 82) | p value |
|---|---|---|---|---|
| Hypertension | 0 (0%) | 0 (0%) | 0 (0%) | NA |
| Hypotension | 7 (8.3%) | 3 (3.5%) | 3 (3.7%) | 0.335b |
| Bradycardia (<50 beats/min) | 0 (0%) | 0 (0%) | 2 (2.4%) | 0.106b |
| Tachycardia (>100 beats/min) | 0 (0%) | 0 (0%) | 0 (0%) | NA |
| Respiratory depression | 7 (8.3%) | 3 (3.5%) | 7 (8.5%) | 0.342a |
| Chin lift | 7 (8.3%) | 10 (11.8%) | 7 (8.5%) | 0.697a |
| Cough | 1 (1%) | 1 (1%) | 1 (1%) | >0.999b |
| Injection pain | 0 (0%) | 0 (0%) | 0 (0%) | NA |
| Pharyngeal inlet | 3 (3.6%) | 3 (3.5%) | 3 (3.7%) | >0.999b |
| Dysphoria | 3 (3.6%) | 11 (12.9%) | 6 (7.3%) | 0.078a |
| Nausea/vomiting | 0 (0%) | 0 (0%) | 0 (0%) | NA |
| Awareness | 0 (0%) | 0 (0%) | 0 (0%) | NA |
| Delirium | 0 (0%) | 0 (0%) | 0 (0%) | NA |
NA, not applicable.
Values are reported as frequency (%).
aObtained from a Chi-square test.
bObtained from a Fisher’s exact test.